Literature DB >> 35475723

Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens.

Antigona Ulndreaj1, Mingyue Wang2, Salvia Misaghian2, Louis Paone2, George B Sigal2, Martin Stengelin2, Christopher Campbell2, Logan R Van Nynatten3,4, Antoninus Soosaipillai5, Atefeh Ghorbani6, Anu Mathew2, Douglas D Fraser3,4, Eleftherios P Diamandis1,5,6,7, Ioannis Prassas1,5.   

Abstract

OBJECTIVES: Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19) presents occasionally with an aberrant autoinflammatory response, including the presence of elevated circulating autoantibodies in some individuals. Whether the development of autoantibodies against self-antigens affects COVID-19 outcomes remains unclear. To better understand the prognostic role of autoantibodies in COVID-19, we quantified autoantibodies against 23 markers that are used for diagnosis of autoimmune disease. To this end, we used serum samples from patients with severe [intensive care unit (ICU)] and moderate (ward) COVID-19, across two to six consecutive time points, and compared autoantibody levels to uninfected healthy and ICU controls.
METHODS: Acute and post-acute serum (from 1 to 26 ICU days) was collected from 18 ICU COVID-19-positive patients at three to six time points; 18 ICU COVID-19-negative patients (sampled on ICU day 1 and 3); 21 ward COVID-19-positive patients (sampled on hospital day 1 and 3); and from 59 healthy uninfected controls deriving from two cohorts. Levels of IgG autoantibodies against 23 autoantigens, commonly used for autoimmune disease diagnosis, were measured in serum samples using MSD® U-PLEX electrochemiluminescence technology (MSD division Meso Scale Discovery®), and results were compared between groups.
RESULTS: There were no significant elevations of autoantibodies for any of the markers tested in patients with severe COVID-19.
CONCLUSIONS: Sample collections at longer time points should be considered in future studies, for assessing the possible development of autoantibody responses following infection with SARS-CoV-2.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; Intensive care unit (ICU); SARS-CoV-2; autoantibodies; autoimmunity; electrochemiluminescence; prognostic markers; severe disease

Mesh:

Substances:

Year:  2022        PMID: 35475723      PMCID: PMC9128368          DOI: 10.1515/cclm-2022-0239

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   8.490


  22 in total

1.  Interpreting Diagnostic Tests for SARS-CoV-2.

Authors:  Nandini Sethuraman; Sundararaj Stanleyraj Jeremiah; Akihide Ryo
Journal:  JAMA       Date:  2020-06-09       Impact factor: 56.272

2.  Antibody responses to SARS-CoV-2 in patients with COVID-19.

Authors:  Quan-Xin Long; Bai-Zhong Liu; Hai-Jun Deng; Gui-Cheng Wu; Kun Deng; Yao-Kai Chen; Pu Liao; Jing-Fu Qiu; Yong Lin; Xue-Fei Cai; De-Qiang Wang; Yuan Hu; Ji-Hua Ren; Ni Tang; Yin-Yin Xu; Li-Hua Yu; Zhan Mo; Fang Gong; Xiao-Li Zhang; Wen-Guang Tian; Li Hu; Xian-Xiang Zhang; Jiang-Lin Xiang; Hong-Xin Du; Hua-Wen Liu; Chun-Hui Lang; Xiao-He Luo; Shao-Bo Wu; Xiao-Ping Cui; Zheng Zhou; Man-Man Zhu; Jing Wang; Cheng-Jun Xue; Xiao-Feng Li; Li Wang; Zhi-Jie Li; Kun Wang; Chang-Chun Niu; Qing-Jun Yang; Xiao-Jun Tang; Yong Zhang; Xia-Mao Liu; Jin-Jing Li; De-Chun Zhang; Fan Zhang; Ping Liu; Jun Yuan; Qin Li; Jie-Li Hu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-04-29       Impact factor: 53.440

3.  A proteome-wide immuno-mass spectrometric identification of serum autoantibodies.

Authors:  Milena Music; Antoninus Soosaipillai; Ihor Batruch; Ioannis Prassas; Dimitrios P Bogdanos; Eleftherios P Diamandis
Journal:  Clin Proteomics       Date:  2019-06-20       Impact factor: 3.988

4.  Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.

Authors:  F Galeano-Valle; C M Oblitas; M M Ferreiro-Mazón; J Alonso-Muñoz; J Del Toro-Cervera; M di Natale; P Demelo-Rodríguez
Journal:  Thromb Res       Date:  2020-05-15       Impact factor: 3.944

5.  Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.

Authors:  Uriel Trahtemberg; Robert Rottapel; Claudia C Dos Santos; Arthur S Slutsky; Andrew Baker; Marvin J Fritzler
Journal:  Ann Rheum Dis       Date:  2021-04-26       Impact factor: 19.103

Review 6.  Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies.

Authors:  Jan Damoiseaux; Arad Dotan; Marvin J Fritzler; Dimitrios P Bogdanos; Pier Luigi Meroni; Dirk Roggenbuck; Michel Goldman; Nils Landegren; Paul Bastard; Yehuda Shoenfeld; Karsten Conrad
Journal:  Autoimmun Rev       Date:  2021-12-09       Impact factor: 9.754

7.  A living WHO guideline on drugs for covid-19

Authors:  Arnav Agarwal; Bram Rochwerg; François Lamontagne; Reed Ac Siemieniuk; Thomas Agoritsas; Lisa Askie; Lyubov Lytvyn; Yee-Sin Leo; Helen Macdonald; Linan Zeng; Wagdy Amin; André Ricardo Araujo da Silva; Diptesh Aryal; Fabian AJ Barragan; Frederique Jacquerioz Bausch; Erlina Burhan; Carolyn S Calfee; Maurizio Cecconi; Binila Chacko; Duncan Chanda; Vu Quoc Dat; An De Sutter; Bin Du; Stephen Freedman; Heike Geduld; Patrick Gee; Matthias Gotte; Nerina Harley; Madiha Hashimi; Beverly Hunt; Fyezah Jehan; Sushil K Kabra; Seema Kanda; Yae-Jean Kim; Niranjan Kissoon; Sanjeev Krishna; Krutika Kuppalli; Arthur Kwizera; Marta Lado Castro-Rial; Thiago Lisboa; Rakesh Lodha; Imelda Mahaka; Hela Manai; Marc Mendelson; Giovanni Battista Migliori; Greta Mino; Emmanuel Nsutebu; Jacobus Preller; Natalia Pshenichnaya; Nida Qadir; Pryanka Relan; Saniya Sabzwari; Rohit Sarin; Manu Shankar-Hari; Michael Sharland; Yinzhong Shen; Shalini Sri Ranganathan; Joao P Souza; Miriam Stegemann; Ronald Swanstrom; Sebastian Ugarte; Tim Uyeki; Sridhar Venkatapuram; Dubula Vuyiseka; Ananda Wijewickrama; Lien Tran; Dena Zeraatkar; Jessica J Bartoszko; Long Ge; Romina Brignardello-Petersen; Andrew Owen; Gordon Guyatt; Janet Diaz; Leticia Kawano-Dourado; Michael Jacobs; Per Olav Vandvik
Journal:  BMJ       Date:  2020-09-04

8.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

Authors:  Paul Bastard; Zhiyong Liu; Jérémie Le Pen; Marcela Moncada-Velez; Jie Chen; Masato Ogishi; Ira K D Sabli; Stephanie Hodeib; Cecilia Korol; Jérémie Rosain; Kaya Bilguvar; Junqiang Ye; Alexandre Bolze; Benedetta Bigio; Rui Yang; Andrés Augusto Arias; Qinhua Zhou; Yu Zhang; Richard P Lifton; Shen-Ying Zhang; Guy Gorochov; Vivien Béziat; Emmanuelle Jouanguy; Vanessa Sancho-Shimizu; Charles M Rice; Laurent Abel; Luigi D Notarangelo; Aurélie Cobat; Helen C Su; Jean-Laurent Casanova; Qian Zhang; Fanny Onodi; Sarantis Korniotis; Léa Karpf; Quentin Philippot; Marwa Chbihi; Lucie Bonnet-Madin; Karim Dorgham; Nikaïa Smith; William M Schneider; Brandon S Razooky; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Leen Moens; Ji Eun Han; Lazaro Lorenzo; Lucy Bizien; Philip Meade; Anna-Lena Neehus; Aileen Camille Ugurbil; Aurélien Corneau; Gaspard Kerner; Peng Zhang; Franck Rapaport; Yoann Seeleuthner; Jeremy Manry; Cecile Masson; Yohann Schmitt; Agatha Schlüter; Tom Le Voyer; Taushif Khan; Juan Li; Jacques Fellay; Lucie Roussel; Mohammad Shahrooei; Mohammed F Alosaimi; Davood Mansouri; Haya Al-Saud; Fahd Al-Mulla; Feras Almourfi; Saleh Zaid Al-Muhsen; Fahad Alsohime; Saeed Al Turki; Rana Hasanato; Diederik van de Beek; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio'; Paolo Bonfanti; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Andrew J Oler; Miranda F Tompkins; Camille Alba; Isabelle Vandernoot; Jean-Christophe Goffard; Guillaume Smits; Isabelle Migeotte; Filomeen Haerynck; Pere Soler-Palacin; Andrea Martin-Nalda; Roger Colobran; Pierre-Emmanuel Morange; Sevgi Keles; Fatma Çölkesen; Tayfun Ozcelik; Kadriye Kart Yasar; Sevtap Senoglu; Şemsi Nur Karabela; Carlos Rodríguez-Gallego; Giuseppe Novelli; Sami Hraiech; Yacine Tandjaoui-Lambiotte; Xavier Duval; Cédric Laouénan; Andrew L Snow; Clifton L Dalgard; Joshua D Milner; Donald C Vinh; Trine H Mogensen; Nico Marr; András N Spaan; Bertrand Boisson; Stéphanie Boisson-Dupuis; Jacinta Bustamante; Anne Puel; Michael J Ciancanelli; Isabelle Meyts; Tom Maniatis; Vassili Soumelis; Ali Amara; Michel Nussenzweig; Adolfo García-Sastre; Florian Krammer; Aurora Pujol; Darragh Duffy
Journal:  Science       Date:  2020-09-24       Impact factor: 47.728

9.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Authors:  Paul Bastard; Lindsey B Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; Quentin Philippot; Jérémie Rosain; Vivien Béziat; Steven M Holland; Guy Gorochov; Emmanuelle Jouanguy; Charles M Rice; Aurélie Cobat; Luigi D Notarangelo; Laurent Abel; Helen C Su; Jean-Laurent Casanova; Jérémy Manry; Elana Shaw; Liis Haljasmägi; Pärt Peterson; Lazaro Lorenzo; Lucy Bizien; Sophie Trouillet-Assant; Kerry Dobbs; Adriana Almeida de Jesus; Alexandre Belot; Anne Kallaste; Emilie Catherinot; Yacine Tandjaoui-Lambiotte; Jeremie Le Pen; Gaspard Kerner; Benedetta Bigio; Yoann Seeleuthner; Rui Yang; Alexandre Bolze; András N Spaan; Ottavia M Delmonte; Michael S Abers; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Lorenzo Piemonti; Fabio Ciceri; Kaya Bilguvar; Richard P Lifton; Marc Vasse; David M Smadja; Mélanie Migaud; Jérome Hadjadj; Benjamin Terrier; Darragh Duffy; Lluis Quintana-Murci; Diederik van de Beek; Lucie Roussel; Donald C Vinh; Stuart G Tangye; Filomeen Haerynck; David Dalmau; Javier Martinez-Picado; Petter Brodin; Michel C Nussenzweig; Stéphanie Boisson-Dupuis; Carlos Rodríguez-Gallego; Guillaume Vogt; Trine H Mogensen; Andrew J Oler; Jingwen Gu; Peter D Burbelo; Jeffrey I Cohen; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio; Paolo Bonfanti; Patrick Rossignol; Julien Mayaux; Frédéric Rieux-Laucat; Eystein S Husebye; Francesca Fusco; Matilde Valeria Ursini; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Xavier Duval; Jade Ghosn; John S Tsang; Raphaela Goldbach-Mansky; Kai Kisand; Michail S Lionakis; Anne Puel; Shen-Ying Zhang
Journal:  Science       Date:  2020-09-24       Impact factor: 63.714

10.  Drug treatments for covid-19: living systematic review and network meta-analysis

Authors:  Reed Ac Siemieniuk; Jessica J Bartoszko; Dena Zeraatkar; Elena Kum; Anila Qasim; Juan Pablo Díaz Martinez; Ariel Izcovich; Francois Lamontagne; Mi Ah Han; Arnav Agarwal; Thomas Agoritsas; Maria Azab; Gonzalo Bravo; Derek K Chu; Rachel Couban; Tahira Devji; Zaira Escamilla; Farid Foroutan; Ya Gao; Long Ge; Maryam Ghadimi; Diane Heels-Ansdell; Kimia Honarmand; Liangying Hou; Quazi Ibrahim; Assem Khamis; Bonnie Lam; Christian Mansilla; Mark Loeb; Anna Miroshnychenko; Maura Marcucci; Shelley L McLeod; Sharhzad Motaghi; Srinivas Murthy; Reem A Mustafa; Hector Pardo-Hernandez; Gabriel Rada; Yamna Rizwan; Pakeezah Saadat; Charlotte Switzer; Lehana Thabane; George Tomlinson; Per O Vandvik; Robin Wm Vernooij; Andrés Viteri-García; Ying Wang; Liang Yao; Yunli Zhao; Gordon H Guyatt; Romina Brignardello-Petersen
Journal:  BMJ       Date:  2020-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.